WO2010096186A1 - Analogues of neuropeptide y having at least one synthetic amino acid substitution - Google Patents

Analogues of neuropeptide y having at least one synthetic amino acid substitution Download PDF

Info

Publication number
WO2010096186A1
WO2010096186A1 PCT/US2010/000491 US2010000491W WO2010096186A1 WO 2010096186 A1 WO2010096186 A1 WO 2010096186A1 US 2010000491 W US2010000491 W US 2010000491W WO 2010096186 A1 WO2010096186 A1 WO 2010096186A1
Authority
WO
WIPO (PCT)
Prior art keywords
aib
4hyp
seq
hnpy
substituted
Prior art date
Application number
PCT/US2010/000491
Other languages
French (fr)
Inventor
Zheng Xin Dong
Kevin L. Zhou
Daniel B. Deoliveira
Original Assignee
Ipsen Pharma S.A.S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma S.A.S filed Critical Ipsen Pharma S.A.S
Priority to EA201171075A priority Critical patent/EA019498B1/en
Priority to US13/202,030 priority patent/US8440611B2/en
Priority to AU2010216383A priority patent/AU2010216383B2/en
Priority to JP2011551067A priority patent/JP5480301B2/en
Priority to CN201080008613.XA priority patent/CN102325540B/en
Priority to EP10744070A priority patent/EP2398485A4/en
Priority to CA2751636A priority patent/CA2751636C/en
Priority to UAA201111164A priority patent/UA101435C2/en
Priority to MX2011008776A priority patent/MX2011008776A/en
Priority to KR1020117020922A priority patent/KR101345253B1/en
Publication of WO2010096186A1 publication Critical patent/WO2010096186A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively """ bind to the neuropeptide Yl receptor subtype compared to the neuropeptide Y2 receptor subtype.
  • Neuropeptide Y a 36 amino acid peptide neurotransmitter, is a member of the pancreatic family of peptides and shares significant sequence homology with pancreatic polypeptide and peptide YY.
  • Human neuropeptide Y (“hNPY”) has the sequence: H-Tyr- Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr- Ser- Ala-Leu- Arg-His-Tyr-Ile-Asn-Leu-Ile- Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ ID NO:1).
  • NPY was discovered, isolated and sequenced from porcine brain and was named "neuropeptide Y” due to its isolation from neural tissue and the presence of tyrosine as both the amino and carboxy terminal amino acid.
  • NPY and the other members of its family of peptides all feature a tertiary structure consisting of an N-terminal polyproline helix and an amphiphilic ⁇ -helix, connected with a ⁇ - turn, creating a hairpin-like loop, which is sometimes referred to as the "pancreatic polypeptide fold.”
  • the helices are kept together by hydrophobic interactions.
  • the amidated C-terminal end projects away from the hairpin loop.
  • NPY neuropeptide derived from the central nervous system with widespread distribution including the cortex, brainstem, hippocampus, hypotahlamus, amygdala, and thalamus, as well as being present in the peripheral nervous system in sympathetic neurons and adrenal chromaffin cells.
  • NPY seems to fulfill the main neurotransmitter criteria, since it is stored in synaptic granules, is released upon electrical nerve stimulation, and acts at specific receptors. It is clear that NPY is an important messenger in its own right, probably in the brain, where NPY potently inhibits the activity of adenylate cyclase and induces an increase in the intracellular levels of calcium. Central injection of NPY results in blood pressure changes, increased feeding, increased fat storage, elevated blood sugar and insulin, decreased locomotor activity, reduced body temperature, and catalepsy. NPY appears to interact with a family of closely related receptors.
  • the Yl receptor subtype (“NPY-Yl receptor”) appears to be the major vascular NPY receptor.
  • the Y2 receptor subtype (“NPY- Y2 receptor”) can also occur postjunctionally on vascular smooth muscle.
  • the Y3 receptor subtype (“NPY- Y3 receptor”) appears to be NPY-specific, not binding PYY. This receptor is likely to be present in the adrenal tissues, medulla, heart, and brain stem, among other areas.
  • Patent Cooperation Treaty Publication No. WO 95/00161 describes a series of NPY antagonists and agonists for controlling biological activities such as obesity and cardiovascular function.
  • physiological disorders related to an excess of neuropeptide Y include: disorders or diseases pertaining to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction, sudden cardiac death, arrythmia, peripheral vascular disease, and abnormal renal conditions such as impaired flow of fluid, abnormal mass transport, or renal failure; conditions related to increased sympathetic nerve activity for example, during or after coronary artery surgery, and operations and surgery in the gastrointestinal tract; cerebral diseases and diseases related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, and conditions related to stroke, cerebral vasospasm and hemmorrhage, depression, anxiety, schizophrenia, and dementia; conditions related to pain or nociception; diseases related to abnormal gastrointenstinal motility and secretion, such as different forms of ileus, urinary incontinence, and
  • the present invention provides peptide variants of hNPY of the following formula (I) (SEQ ID NO:2):
  • a 1 is Tyr, (X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 2 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
  • a 3 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 4 is Lys, Arg, hArg, Dab, Dap, Orn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 5 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
  • a 6 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 7 is Asn, Aib, GIn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 8 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
  • a 9 is GIy, Aib, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 10 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 11 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 12 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 13 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
  • a 14 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 15 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 16 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 17 is Met, Ace, Aib, Cha, He, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 18 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 19 is Arg, hArg, Ape, Dab, Dap, Lys, Orn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 20 is Tyr, (X ⁇ X 2 ,X 3 ,X 4 ,X 5 )Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 21 is Tyr, (X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 22 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 23 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 24 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))- C(O);
  • a 25 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 26 is His, 2PaI, 3PaI, 4PaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 27 is Tyr, (X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 28 is lie, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))- C(O);
  • a 29 is Asn, Aib, GIn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 30 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-
  • a 31 is He, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-
  • a 32 is Thr, Aib, Ser, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 33 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 34 is GIn, Asn, Dhp, 3Hyp, cis-3Hyp, 4Hyp, cis-4Hyp, Inp, Ktp, Nip, Oic, hPro, Tic, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 35 is Arg, Aic, Ape, hArg, Dab, Dap, Lys, Orn, NH 2 Phe, NH 2 CH 2 Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 36 is Tyr, Aic, (X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 37 is HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O) or deleted;
  • R 1 is OH, NH 2 , (C 1-30 )alkoxy, or NH-X 6 -CH 2 -X 7 , wherein X 6 is a (C 1-40 )alkyl or (C 2- 40 )alkenyl, and wherein X 7 is H, OH, CO 2 H, or C(O)-NH 2 ;
  • R 2 and R 3 each is, independently for each occurrence, selected from the group consisting of H, (Ci -30 )alkyl, (Q. ⁇ heteroalkyl, (Ci -30 )acyl, (C 2-3 o)alkenyl, (C 2-30 )alkynyl, aryl(C 1-3 o)alkyl, aryl(Ci -30 )acyl, substituted (C 1-30 )alkyl, substituted (C 1 .
  • R 3 is H, (C 1-30 )alkyl, (C 1-30 )heteroalkyl, (C 2-3 o)alkenyl, (C 2-30 )alkynyl, substituted aryl(Ci -3 o)alkyl, and substituted 8TyI(C 1 -3 o)acyl; provided that when R 2 is (C 1-30 )acyl, aryl(C 1-30 )acyl, substituted (C2 -30 )acyl, or substituted aryl(C 1-30 )acyl, R 3 is H, (C 1-30 )alkyl, (C 1-30 )heteroalkyl, (C 2-3 o)alkenyl, (C 2- 30 )alkynyl, aryl(Ci -30 )alkyl, substituted (C 1-30 )alkyl, substituted (Ci -30 )heteroalkyl, substituted (C 2-3 o)alkenyl, substituted (C 2-3 o)
  • a subset (IA) of the compounds covered by the above formula I are those in which: A 1 is Tyr;
  • a 2 is Pro
  • a 3 is Ser or Aib
  • a 4 is Lys
  • a 5 is Pro;
  • a 6 is Asp or Aib;
  • a 7 is Asn or Aib
  • a 8 is Pro
  • a 9 is GIy or Aib
  • a 10 is GIu or Aib;
  • a 11 is Asp or Aib;
  • a 12 is Ala or Aib
  • a 13 is Pro
  • a 14 is Ala or Aib;
  • a 15 is GIu or Aib;
  • a 16 is Asp or Aib
  • a 17 is Met, A6c, Aib, or NIe;
  • a 18 is Ala or Aib
  • a 19 is Arg;
  • a 20 is Tyr;
  • a 22 is Ser or Aib
  • a 23 is Ala or Aib
  • a 24 is Leu or A6c;
  • a 25 is Arg;
  • a 26 is His
  • a 27 is Tyr
  • a 28 is He or A6c
  • a 29 is Asn or Aib;
  • a 30 is Leu or A6c;
  • a 31 is He, A6c, or Leu;
  • a 32 is Thr or Aib
  • a 33 is Arg
  • a 34 is Dhp, 4Hyp, Inp, Nip, hPro, Tic, or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);
  • a 35 is Arg, Ape, Lys, 4NH 2 Phe, or 4NH 2 CH 2 Phe;
  • a 36 is Tyr or Aic
  • R 1 is NH 2 ;
  • R 2 and R 3 each is, independently for each occurrence, H or (C 1-3 o)acyl; provided that when R 2 is (C 1-30 )acyl, R 3 is H;
  • R 4 and R 5 each is, independently for each occurrence, H or (Ci-4o)acyl; n is 4; and
  • X 1 , X 2 , X 3 , X 4 , and X 5 each is, independently for each occurrence, H, CH 2 NH 2 , or NH 2 .
  • the peptide bond between A 35 and A 36 may be replaced by a pseudopeptide bond, wherein A 35 -A 36 may be Lys- ⁇ (CH 2 -NH)Tyr or Lys- ⁇ (CH 2 -N(Ac))Tyr.
  • a 34 is preferably 4Hyp.
  • HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O) is preferably
  • Preferred compounds of the formula (I) or the subset (IA) are:
  • Example 1 [Aib 10 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:3)
  • Example 2 [Aib 17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:4)
  • Example 3 [Aib 11 ' 17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:5)
  • Example 7 [A6c 30 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:9)
  • Example 8 [A6c 28 , 4Hyp 34 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:10)
  • Example 12 [Aib 18 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:14)
  • Example 13 [Aib 29 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:15)
  • Example 14 [Aib 32 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:16)
  • Example 17 [Aib 11 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:19)
  • Example 18 [Aib 12 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:20)
  • Example 20 [Aib 15 , 4Hyp 34 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:22)
  • Example 21 [Aib 16 , 4Hyp 34 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:23)
  • Example 22 [Aib 7 , 4Hyp 34 ]hNP Y(I -3 O)-NH 2 ; (SEQ ID NO: 24)
  • Example 23 [Aib 9 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:25)
  • Example 24 [Aib 10>17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:26)
  • Example 25 [Aib 15 ' 17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:27)
  • Example 26 [Aib 11 ' 15 , NIe 17 , 4Hyp 34 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:28)
  • Example 27 [Aib 10 ' 15 , NIe 17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:29)
  • Example 28 [Aib 11 ' 15 ' 17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:30)
  • Example 30 [Aib 10>15>17 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:32)
  • Example 31 [Aib 11>16 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:33)
  • Example 32 [Aib 10 ' 16 , 4Hyp 34 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:34)
  • Example 33 [Aib 11 ' 17 , 4Hyp 34 , Lys 35 - ⁇ (CH 2 -N(Ac))Tyr 36 ]hNPY(l-36)-NH 2 ;
  • Example 34 [Aib 17 , 4Hyp 34 , Apc 35 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:36)
  • Example 35 [Aib 17 , 4Hyp 34 , Aic 36 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:37)
  • Example 36 [Aib 17 , 4Hyp 34 , 4NH 2 Phe 35 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:38)
  • Example 37 [Aib 17 , 4Hyp 34 , 4NH 2 CH 2 Phe 35 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:39)
  • Example 38 [Aib 17 , 4Hyp 34 , Lys 35 - ⁇ (CH 2 -NH)Tyr 36 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:40)
  • Example 39 [Aib 11 ' 17 , 4Hyp 34 , Lys 35 - ⁇ (CH 2 -NH)Tyr 36 ]hNPY(l-36)-NH 2 ; (SEQ ID NO:41)
  • Example 40 [Nip 34 ]hNPY( 1-3 O)-NH 2 ; (SEQ ID NO:42)
  • Example 44 [Tic 34 ]hNPY(l-36)-NH 2 ; and (SEQ ID NO:46)
  • Example 45 [Leu 31 , Lys 34 (N ⁇ -C(O)-(CH 2 )i 2 -CH 3 )]hNPY(l-36)-NH 2 . (SEQ ID NO:47)
  • amino acid refers to any natural or unnatural amino acid, including but not limited to ⁇ -amino acids, ⁇ -amino acids, or ⁇ -amino acids, and may be either D- or L-amino acid unless otherwise indicated.
  • the abbreviation stands for the structure of (R 2 R 3 )-N-C(R)(R')-CO-, wherein R 2 and R 3 are as defined in the formula (I).
  • a peptide of this invention is also denoted by another format, e.g., [Pro 34 ] hNP Y(I- 36)-NH 2 (SEQ ID NO:48), with the substituted amino acids from the natural sequence placed between the brackets, e.g. , Pro for GIn in hNPY.
  • the designation "NH 2 " in hNPY( 1 -36)- NH 2 (SEQ TD NO:1) indicates that the C-terminus of the peptide is amidated whereas hNPY(l-36)-OH (SEQ ID NO:49) indicates the free acid form.
  • A3c represents 1 -amino- 1-cyclopropanecarboxylic acid
  • A4c represents 1 -amino- 1-cyclobutanecarboxylic acid
  • A5c represents 1 -amino- 1-cyclopentanecarboxylic acid; and A6c represents 1 -amino- 1-cyclohexanecarboxylic acid
  • 3Hyp trans-3-hydroxy-L-proline i.e., (2S, 3S)-3-hydroxypyrrolidine-2- carboxylic acid cis-3Hyp cis-3-hydroxy-L-proline, i.e., (2S, 3R)-3-hydroxypyrrolidine-2- carboxylic acid
  • 4Hyp 4-hydroxyproline i.e., (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid cis-4Hyp cis-4-hydroxy-L-proline, i.e., (2S, 4S)-4-hydroxypyrrolidine-2- carboxylic acid He or I isoleucine
  • N 8 indicates that the entity within the parentheses is coupled to the epsilon-nitrogen of the Lys sidechain Nva norvaline Oic octahydroindole-2-carboxylic acid
  • Lys- ⁇ (CH2 -NH)Tyr has the structure of:
  • the Greek letter psi " ⁇ " is used herein to indicate that a peptide bond has been replaced by a pseudopeptide bond.
  • the format of the ⁇ term is A- ⁇ (X-X')-B wherein A is the amino acyl radical whose carbonyl group has been modified to X and B the amino acyl radical whose ⁇ -amino groups has been modified to X'.
  • X and X' are shown as strings of element symbols, separated by a bond, e.g., Lys- ⁇ (CH 2 -NH)-Tyr.
  • Alkyl refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds, examples of which include but are not limited to methyl, ethyl, propyl and butyl.
  • the alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups, examples of which include, but are not limited to, isopropyl and tertbutyl.
  • Substituted alkyl refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH 2 , NHCH 3 , NO 2 , (C 1-2 ) alkyl substituted with 1 to 6 halogens, CF 3 , OCH 3 , OCF 3 , and (CH 2 ) 0-4 -COOH. In different embodiments, 1, 2, 3 or 4 substituents are present.
  • the presence of (CH 2 ) O-4 -COOH results in the production of an alkyl acid.
  • alkyl acids containing (CH 2 ) O-4 -COOH include, but are not limited to, 2-norbornane acetic acid, tert-butyric acid and 3-cyclopentyl propionic acid.
  • Heteroalkyl refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group are replaced with one or more of the following atoms or groups: amino, amido, O, S, N, and carbonyl. hi different embodiments, 1 or 2 heteroatoms are present.
  • Substituted heteroalkyl refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH 2 , NHCH 3 , NO 2 , (C 1-2 ) alkyl substituted with 1 to 6 halogens, CF 3 , OCH 3 , OCF 3 , and (CH 2 ) O-4 -COOH. hi different embodiments, 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine, and iodine
  • alkenyl refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present, examples of which include, but are not limited to, vinyl, allyl, butenyl and propenyl.
  • the alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups, examples of which include, but are not limited to, n-butenyl versus t-butenyl, and n-pentenyl compared to cyclopentenyl.
  • Substituted alkenyl refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH 2 , NHCH 3 , NO 2 , (C 1-2 ) alkyl substituted with 1 to 6 halogens, CF 3 , OCH 3 , OCF 3 , and (CH 2 ) 0-4 -COOH. In different embodiments, 1, 2, 3 or 4 substituents are present.
  • halogen i.e., fluorine, chlorine, bromine, and iodine
  • OH OH
  • CN SH
  • Aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated ⁇ -electron system containing up to two conjugated or fused ring systems.
  • Aryl includes, but is not limited to, carboxylic aryl, heterocyclic aryl and biaryl groups.
  • an aryl is a 5- or 6-membered ring.
  • Preferred atoms for a heterocyclic aryl include, but are not limited to, one or more of sulfur, oxygen and nitrogen. Examples of aryl include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and 9-anthracene.
  • Aryl substituents are selected from the group consisting Of(Ci -4 ) alkyl, (C 1-4 ) alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH 2 , NO 2 , (C 1-2 ) alkyl substituted with 1 to 5 halogens, CF 3 , OCF 3 , and (CH 2 ) 0-4 -COOH.
  • aryl contains O, 1, 2, 3 or 4 substituents.
  • Alkylaryl refers to an “alkyl” joined to an “aryl,” as defined above.
  • cycloalkyl is intended to include a mono-cycloalkyl group or a bi- cycloalkyl group of the indicated carbon number known to those of skill in the art.
  • heterocycle includes mono-cyclic and bi-cyclic systems having one or more heteroatoms, such as oxygen, nitrogen and sulfur.
  • the ring systems may be aromatic, for example, pyridine, indole, quinoline, pyrimidine, thiophene (also known as thienyl), furan, benzothiophene, tetrazole, dihydroindole, indazole, N-formylindole, benzimidazole, thiazole, and thiadiazole.
  • the ring systems also may be non-aromatic, for example, but not limited to, pyrrolidine, piperidine, morpholine, and the like.
  • a polypeptide region of an NPY analogue can be chemically or biochemically synthesized and/or modified. See, e.g., Stewart, J. M., et al, Solid Phase Synthesis, Pierce Chemical Co., 2d ed. (1984); and see, e.g., Sambrook et al, Molecular Cloning, A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press (1989) for examples of techniques for biochemical synthesis involving the introduction of a nucleic acid into a cell and expression of nucleic acids.
  • Example 1 TAib 10 . 4Hvp 34 1hNPY(l-36VNH 2
  • the titled peptide was assembled using Fmoc-chemistry.
  • the C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale.
  • the reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 minutes to swell the resin.
  • the ABI FastMoc 1.0 ® protocol was used to generate the peptide.
  • Each cycle comprised of deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing.
  • Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBT/HBTU. After enough time was allotted for dissolution of the amino acid, it was automatically transferred to the activation vessel.
  • Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step.
  • DIPEA 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
  • the standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine, containing 0.1M HOBT, in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0 C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment, except that it was for a 3 -minute duration.
  • Residues 9-10 contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0 C maximum temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF.
  • Cycle 20 Fmoc-Met-OH; Cycle 21) Fmoc- Asp(OtBu)-OH; Cycle 22) Fmoc-Glu(OtBu)-OH; Cycle 23) Fmoc-Ala-OH; Cycle 24) Fmoc- Pro-OH; Cycle 25) Fmoc-Ala-OH; Cycle 26) Fmoc-Asp(OtBu)-OH; Cycle 27) Fmoc-Aib- OH; Cycle 28) Fmoc-Gly-OH; Cycle 29) Fmoc-Pro-OH; Cycle 30) Fmoc-Asn(Trt)-OH; Cycle 31) Fmoc-Asp(OtBu)-OH; Cycle 32) Fmoc-Pro-OH; Cycle 33) Fmoc-Lys(Boc)-OH; Cycle 34) Fmoc-Ser(tBu)-OH; Cycle 35) Fmoc-Met-OH; Cycle 21) Fmoc- Asp(Ot
  • the resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours.
  • the filtrate was collected into 45 ml of cold anhydrous ethyl ether.
  • the precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge.
  • the ether was decanted and the peptide re-suspended in fresh ether.
  • the ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether.
  • the peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 4212.1, corresponding to the desired product. Analytical HPLC analysis, employing a 250 x 4.6 mm Cl 8 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes, identified a main product with 45% purity.
  • the crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate.
  • the purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4212.8 da), with the experimental mass corresponding well to the expected mass of 4212.7.
  • the peptide was subsequently lyophilized producing 39 mg of purified product representing a 9% yield.
  • the titled peptide was assembled using Fmoc-chemistry.
  • the C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale.
  • the reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 minutes to swell the resin.
  • the ABI FastMoc 1.0 ® protocol was used to generate the peptide.
  • Each cycle comprised deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing.
  • Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBTVHBTU. After the amino acid had dissolved, it was automatically transferred to the activation vessel.
  • Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step.
  • DIPEA 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
  • the resin from the previous synthesis was placed in a 50 ml conical tube along with 15 ml of DMF and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process.
  • the standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used involving deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine containing 0.1M HOBT in DMF.
  • the initial deprotection step lasted 30 seconds with microwave power (45 watts, maximum temperature of 75 0 C) and nitrogen bubbling (3 seconds on / 7 seconds off).
  • the reaction vessel was then drained and a second piperidine treatment, identical to the first treatment was applied for 3 minutes.
  • the resin was then drained and thoroughly washed with DMF several times.
  • the protected amino acid, Fmoc-Aib-OH prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 equivalents) followed by 1.0 ml of 0.45M (4.5 eq.) HBTU in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA in NMP.
  • the coupling step was performed for 5 minutes using 20 watts of microwave power, at a maximum temperature of 75 0 C, and the same rate of nitrogen bubbling. Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated.
  • Residues 16-17 contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride containing 0.015M HOBT in NMP along with 2 ml of the 2M DIPEA solution using a multi- step microwave protocol: 50 watts of power for 30 seconds (65 0 C maximum temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF.
  • Cycle 20 Fmoc-Aib-OH; Cycle 21) Fmoc-Asp(OtBu)-OH; Cycle 22) Fmoc-Glu(OtBu)-OH; Cycle 23) Fmoc-Ala-OH; Cycle 24) Fmoc-Pro-OH; Cycle 25) Fmoc-Ala-OH; Cycle 26) Fmoc-Asp(OtBu)-OH; Cycle 27) Fmoc- GIu(OtBu)-OH; Cycle 28) Fmoc-Gly-OH; Cycle 29) Fmoc-Pro-OH; Cycle 30) Fmoc- Asn(Trt)-OH; Cycle 31) Fmoc-Asp(OtBu)-OH; Cycle 32) Fmoc-Pro-OH; Cycle 33) Fmoc- Lys(Boc)-OH; Cycle 34) Fmoc-Ser(tBu)-OH
  • the resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours.
  • the filtrate was collected into 45 ml of cold anhydrous ethyl ether.
  • the precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge.
  • the ether was decanted and the peptide re-suspended in fresh ether.
  • the ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether.
  • the peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve.
  • the peptide solution was then analyzed by mass spectrometry.
  • Mass analysis employing electrospray ionization identified a main product containing a mass of 4210.8, corresponding to the desired product.
  • Analytical HPLC analysis employing a 250 x 4.6 mm Cl 8 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes, identified a main product with 54% purity.
  • the crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate.
  • the purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4210.6 da) with the experimental mass corresponding to the expected mass of 4210.6.
  • the peptide was subsequently lyophilized producing 53 mg of purified product representing a 13% yield.
  • the titled peptide was assembled using Fmoc-chemistry.
  • the C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale.
  • the reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 min to swell the resin.
  • the ABI FastMoc 1.0 ® protocol was used to generate the peptide.
  • Each cycle was comprised of deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing.
  • Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBT/HBTU. After the amino acid had dissolved, it was automatically transferred to the activation vessel.
  • Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step.
  • DEPEA 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
  • the standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine containing 0.1M HOBT in DMF. The initial deprotection step lasted 30 seconds with microwave power (45 watts, maximum temperature of 75 0 C) and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment except that it was for a 3-minute duration was applied. The resin was then drained and thoroughly washed with DMF several times.
  • the coupling step was performed for 5 minutes using 20 watts of microwave power at a maximum temperature of 75 0 C and the same rate of nitrogen bubbling. Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated.
  • Cycle 2 which was similar to Cycle 1 was then initiated. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire process.
  • Residues 10-11 and 16-17 contained a capping procedure immediately following each coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride containing 0.015M HOBT in NMP along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0 C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power.
  • the resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours.
  • the filtrate was collected into 45ml of cold anhydrous ethyl ether.
  • the precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge.
  • the ether was decanted and the peptide re-suspended in fresh ether.
  • the ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether.
  • the peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve.
  • the peptide solution was then analyzed by mass spectrometry.
  • Mass analysis employing electrospray ionization identified a main product containing a mass of 4180.7, corresponding to the desired product.
  • Analytical HPLC analysis employing a 250 x 4.6 mm C18 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes identified a main product with 68% purity.
  • the crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate.
  • the purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4180.5 da), with the experimental mass corresponding to the expected mass of 4180.6.
  • the peptide was subsequently lyophilized producing 53 mg of purified product representing a 13% yield.
  • Human neuroblastoma cell lines SK-N-MC and SK-N-BE2 (American Type Culture Collection, Rockville, MD, USA), expressing the NPY-Yl and NPY-Y2 receptors, respectifully, were cultured in EMEM containing 10% fetal calf serum and 5% chicken embryo extract, and maintained at 37 °C in a humidifed atmosphere of and 95% air and 5% CO 2 .
  • the appropriate cells (SK-N-MC for NPY-Yl; SK-N-BE2 for NPY- Y2) were harvested, homogenized in 20 ml of ice-cold 50 mM Tris-HCl with a Brinkman Polytron (Westbury, NY, USA) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were resuspended in 50 mM Tris-HCl, containing 2.5 mM MgCl 2 , 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO, USA), and 0.1% BSA.
  • the peptides of this invention can be provided in the form of pharmaceutically acceptable salts.
  • such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).
  • organic acids e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid
  • inorganic acids e.g., hydrochloric acid, sulfuric acid, or
  • a typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1) 0.
  • an effective dosage for the activities of this invention is in the range of 1 x 10 "7 to 200 mg/kg/day, preferably 1 x 10 "4 to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.
  • the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration, and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include, without limitation, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • Preparations according to this invention for parenteral administration include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
  • non-aqueous solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtering through a bacteria-retaining filter, incorporating sterilizing agents, irradiating, or heating the compositions.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
  • compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications.
  • U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester.
  • U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form.
  • U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan.
  • U.S. Patent No.5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin.
  • PCT publication WO99/38536 teaches absorbable sustained release compositions of a bioactive agent.
  • PCT publication WO00/04916 teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process.
  • PCT publication WO00/09166 teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer.
  • PCT publication WO00/25826 teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non- polymerizable lactone.
  • all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
  • all publications, patent applications, patents and other references mentioned herein are hereby incorporated by reference, each in its entirety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Yl receptor subtype compared to the neuropeptide Y2 receptor subtype.

Description

ANALOGUES OF NEUROPEPTIDE Y HAVING AT LEAST ONE SYNTHETIC
AMINO ACID SUBSTITUTION
FIELD OF THE INVENTION The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively """ bind to the neuropeptide Yl receptor subtype compared to the neuropeptide Y2 receptor subtype.
BACKGROUND OF THE INVENTION
Neuropeptide Y ("NPY"), a 36 amino acid peptide neurotransmitter, is a member of the pancreatic family of peptides and shares significant sequence homology with pancreatic polypeptide and peptide YY. Human neuropeptide Y ("hNPY") has the sequence: H-Tyr- Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr- Ser- Ala-Leu- Arg-His-Tyr-Ile-Asn-Leu-Ile- Thr-Arg-Gln-Arg-Tyr-NH2 (SEQ ID NO:1). NPY was discovered, isolated and sequenced from porcine brain and was named "neuropeptide Y" due to its isolation from neural tissue and the presence of tyrosine as both the amino and carboxy terminal amino acid.
NPY and the other members of its family of peptides all feature a tertiary structure consisting of an N-terminal polyproline helix and an amphiphilic α-helix, connected with a β- turn, creating a hairpin-like loop, which is sometimes referred to as the "pancreatic polypeptide fold." The helices are kept together by hydrophobic interactions. The amidated C-terminal end projects away from the hairpin loop.
Subsequent to its discovery, NPY was identified as being the most abundant peptide in the central nervous system with widespread distribution including the cortex, brainstem, hippocampus, hypotahlamus, amygdala, and thalamus, as well as being present in the peripheral nervous system in sympathetic neurons and adrenal chromaffin cells.
NPY seems to fulfill the main neurotransmitter criteria, since it is stored in synaptic granules, is released upon electrical nerve stimulation, and acts at specific receptors. It is clear that NPY is an important messenger in its own right, probably in the brain, where NPY potently inhibits the activity of adenylate cyclase and induces an increase in the intracellular levels of calcium. Central injection of NPY results in blood pressure changes, increased feeding, increased fat storage, elevated blood sugar and insulin, decreased locomotor activity, reduced body temperature, and catalepsy. NPY appears to interact with a family of closely related receptors. These receptors are generally classified into several subtypes based upon the ability of different tissues and receptors to bind different fragments of neuropeptide Y and the closely related PYY. The Yl receptor subtype ("NPY-Yl receptor") appears to be the major vascular NPY receptor. The Y2 receptor subtype ("NPY- Y2 receptor") can also occur postjunctionally on vascular smooth muscle. The Y3 receptor subtype ("NPY- Y3 receptor") appears to be NPY-specific, not binding PYY. This receptor is likely to be present in the adrenal tissues, medulla, heart, and brain stem, among other areas. For a review of neuropeptide Y and neuropeptide Y receptors, see, e.g., C. Wahlestedt and D. Reis, Annual Review of Pharmacology and Toxicology, 33:309-352 (1993). Patent Cooperation Treaty ("PCT") Publication No. WO 95/00161 describes a series of NPY antagonists and agonists for controlling biological activities such as obesity and cardiovascular function.
European Pat. No. 0759441 and U.S. Pat. No. 5,576,337 report that physiological disorders related to an excess of neuropeptide Y include: disorders or diseases pertaining to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction, sudden cardiac death, arrythmia, peripheral vascular disease, and abnormal renal conditions such as impaired flow of fluid, abnormal mass transport, or renal failure; conditions related to increased sympathetic nerve activity for example, during or after coronary artery surgery, and operations and surgery in the gastrointestinal tract; cerebral diseases and diseases related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, and conditions related to stroke, cerebral vasospasm and hemmorrhage, depression, anxiety, schizophrenia, and dementia; conditions related to pain or nociception; diseases related to abnormal gastrointenstinal motility and secretion, such as different forms of ileus, urinary incontinence, and Crohn's disease; abnormal drink and food intake disorders, such as anorexia and metabolic disorders; diseases related to sexual dysfunction and reproductive disorders; conditions or disorders associated with inflammation; respiratory diseases, such as asthma and conditions related to asthma and bronchoconstriction; and diseases related to abnormal hormone release, such as leutinizing hormone, growth hormone, insulin, and prolactin.
PCT Publication No. WO 02/43776 by Reubi reports on the use of compounds that bind the NPY-Yl receptor for the preparation of a pharmaceutical composition for the diagnosis or treatment of tumors expressing the NPY-Yl receptor, in particular breast cancer, avarian cancer and glioblastoma.
There are numerous patents and patent publications that disclose certain NPY analogues and uses thereof, such as U.S. Pat. No. 5,026,685, U.S. Pat. No. 5,328,899, U.S. Pat. No. 6,511,984, PCT Publication No. WO 02/43776, PCT Publication No. WO2007/039318, etc. Notwithstanding the foregoing, there remains a continuing need for NPY analogues having improved potency and/or selectivity and/or in vivo or in vitro characteristics.
SUMMARY OF THE INVENTION In one aspect, the present invention provides peptide variants of hNPY of the following formula (I) (SEQ ID NO:2):
(R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20- A21-A22-A23-Aa4-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-R1
(I) wherein:
A1 is Tyr, (X1,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A2 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A3 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH2)n-N(R4R5))-C(O);
A4 is Lys, Arg, hArg, Dab, Dap, Orn, or HN-CH((CH2)n-N(R4R5))-C(O); A5 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A6 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A7 is Asn, Aib, GIn, or HN-CH((CH2)n-N(R4R5))-C(O);
A8 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A9 is GIy, Aib, or HN-CH((CH2)n-N(R4R5))-C(O); A10 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH2)n-N(R4R5))-C(O);
A11 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A12 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A13 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp; A14 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A15 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH2)n-N(R4R5))-C(O);
A16 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A17 is Met, Ace, Aib, Cha, He, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A18 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A19 is Arg, hArg, Ape, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O);
A20 is Tyr, (X\X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A21 is Tyr, (X1,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O); A22 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH2)n-N(R4R5))-C(O);
A23 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A24 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))- C(O);
A25 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O); A26 is His, 2PaI, 3PaI, 4PaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A27 is Tyr, (X1,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A28 is lie, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))- C(O);
A29 is Asn, Aib, GIn, or HN-CH((CH2)n-N(R4R5))-C(O); A30 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))-
C(O);
A31 is He, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))-
C(O);
A32 is Thr, Aib, Ser, or HN-CH((CH2)n-N(R4R5))-C(O); A33 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O);
A34 is GIn, Asn, Dhp, 3Hyp, cis-3Hyp, 4Hyp, cis-4Hyp, Inp, Ktp, Nip, Oic, hPro, Tic, or HN-CH((CH2)n-N(R4R5))-C(O);
A35 is Arg, Aic, Ape, hArg, Dab, Dap, Lys, Orn, NH2Phe, NH2CH2Phe, or HN-CH((CH2)n-N(R4R5))-C(O); A36 is Tyr, Aic, (X1 ,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A37 is HN-CH((CH2)n-N(R4R5))-C(O) or deleted;
R1 is OH, NH2, (C1-30)alkoxy, or NH-X6-CH2-X7, wherein X6 is a (C1-40)alkyl or (C2- 40)alkenyl, and wherein X7 is H, OH, CO2H, or C(O)-NH2; R2 and R3 each is, independently for each occurrence, selected from the group consisting of H, (Ci-30)alkyl, (Q.^heteroalkyl, (Ci-30)acyl, (C2-3o)alkenyl, (C2-30)alkynyl, aryl(C1-3o)alkyl, aryl(Ci-30)acyl, substituted (C1-30)alkyl, substituted (C1.3o)heteroalkyl, substituted (C2-30)acyl, substituted (C2-3o)alkenyl, substituted (C2-30)alkynyl, substituted aryl(Ci-3o)alkyl, and substituted 8TyI(C1 -3o)acyl; provided that when R2 is (C1-30)acyl, aryl(C1-30)acyl, substituted (C2-30)acyl, or substituted aryl(C1-30)acyl, R3 is H, (C1-30)alkyl, (C1-30)heteroalkyl, (C2-3o)alkenyl, (C2- 30)alkynyl, aryl(Ci-30)alkyl, substituted (C1-30)alkyl, substituted (Ci-30)heteroalkyl, substituted (C2-3o)alkenyl, substituted (C2-3o)alkynyl, or substituted 8TyI(C1 -30)alkyl; R4 and R5 each is, independently for each occurrence, H, (Ci-4o)alkyl, (C1-
40)heteroalkyl, (C1-40)acyl, (C2-4o)alkenyl, (C2-40)alkynyl, aryl(C1-40)alkyl, aryl(C1-40)acyl, substituted (C1 jκ»)alkyl, substituted (Ci-4o)heteroalkyl, substituted (C1-40)acyl, substituted (C2- 40)alkenyl, substituted (C2-4o)alkynyl, substituted 8TyI(C1 -40)alkyl, substituted 8TyI(C1 -4o)acyl, (C1-4o)alkylsulfonyl, or C(NH)-NH2, wherein when R4 is (C1-4o)acyl, aryl(C1-4o)acyl, substituted (C1-4(OaCyI, substituted 8TyI(C1 ^^acyl, (C1-40)alkylsulfonyl, or C(NH)-NH2, then R5 is H or (C1-C40)SUCyI, (C1-40)heteroalkyl, (C2-4o)alkenyl, (C2-4o)alkynyl, 8TyI(C1 ^0)alkyl, substituted (C1-40)alkyl, substituted (C1-4o)heteτoalkyl, substituted (C2--κ))alkenyl, substituted (C2-4Q)alkynyl, or substituted 8TyI(C1 _4o)alkyl; n is, independently for each occurrence, 1, 2, 3, 4, or 5; X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, F, Cl, Br, I, (C1-
10)alkyl, substituted (C1-10)alkyl, aryl, substituted aryl, OH, CH2NH2, NH2, NO2, or CN; and provided that the compound contains at least one substitution with an unnatural amino acid.
A subset (IA) of the compounds covered by the above formula I, are those in which: A1 is Tyr;
A2 is Pro;
A3 is Ser or Aib;
A4 is Lys;
A5 is Pro; A6 is Asp or Aib;
A7 is Asn or Aib;
A8 is Pro;
A9 is GIy or Aib;
A10 is GIu or Aib; A11 is Asp or Aib;
A12 is Ala or Aib;
A13 is Pro;
A14 is Ala or Aib; A15 is GIu or Aib;
A16 is Asp or Aib;
A17 is Met, A6c, Aib, or NIe;
A18 is Ala or Aib;
A19 is Arg; A20 is Tyr;
A21 Tyr;
A22 is Ser or Aib;
A23 is Ala or Aib;
A24 is Leu or A6c; A25 is Arg;
A26 is His;
A27 is Tyr;
A28 is He or A6c;
A29 is Asn or Aib; A30 is Leu or A6c;
A31 is He, A6c, or Leu;
A32 is Thr or Aib;
A33 is Arg;
A34 is Dhp, 4Hyp, Inp, Nip, hPro, Tic, or HN-CH((CH2)n-N(R4R5))-C(O); A35 is Arg, Ape, Lys, 4NH2Phe, or 4NH2CH2Phe;
A36 is Tyr or Aic;
A37 is deleted;
R1 is NH2;
R2 and R3 each is, independently for each occurrence, H or (C1-3o)acyl; provided that when R2 is (C1-30)acyl, R3 is H;
R4 and R5 each is, independently for each occurrence, H or (Ci-4o)acyl; n is 4; and
X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, CH2NH2, or NH2. In the formula (I) or the subset (IA), the peptide bond between A35 and A36 may be replaced by a pseudopeptide bond, wherein A35-A36 may be Lys-ψ(CH2-NH)Tyr or Lys- ψ(CH2-N(Ac))Tyr. hi the the formula (I) or the subset (IA), A34 is preferably 4Hyp. In the the formula (I) or the subset (IA), HN-CH((CH2)n-N(R4R5))-C(O) is preferably
Lys(Nε-C(O)-(CH2)12-CH3).
Preferred compounds of the formula (I) or the subset (IA) are:
Example 1 : [Aib10, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:3)
Example 2: [Aib17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:4) Example 3: [Aib11'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:5)
Example 4: [4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:6)
Example 5: [Aib22, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:7)
Example 6: [A6c31, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:8)
Example 7: [A6c30, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:9) Example 8: [A6c28, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:10)
Example 9: [Aib3, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:11)
Example 10: [A6c24, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:12)
Example 11 : [Aib6, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ED NO: 13)
Example 12: [Aib18, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:14) Example 13: [Aib29, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:15)
Example 14: [Aib32, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:16)
Example 15: [Aib23, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:17)
Example 16: [A6c17, 4Hyp34]hNPY(l-36)-NH2; (SEQ E) NO:18)
Example 17: [Aib11, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:19) Example 18: [Aib12, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:20)
Example 19: [Aib14, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:21)
Example 20: [Aib15, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:22)
Example 21 : [Aib16, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:23)
Example 22: [Aib7, 4Hyp34]hNP Y(I -3 O)-NH2; (SEQ ID NO: 24) Example 23: [Aib9, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:25)
Example 24: [Aib10>17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:26)
Example 25: [Aib15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:27)
Example 26: [Aib11'15, NIe17, 4Hyp34]hNPY( 1-3 O)-NH2; (SEQ ID NO:28) Example 27: [Aib10'15, NIe17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:29)
Example 28: [Aib11'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:30)
Example 29: [Aib12'15>17, 4Hyp34]hNPY(l-36)-NH2; (SEQ E) NO:31)
Example 30: [Aib10>15>17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:32) Example 31: [Aib11>16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:33)
Example 32: [Aib10'16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:34)
Example 33: [Aib11'17, 4Hyp34, Lys35-ψ(CH2-N(Ac))Tyr36]hNPY(l-36)-NH2;
(SEQ ID NO:35)
Example 34: [Aib17, 4Hyp34, Apc35]hNPY(l-36)-NH2; (SEQ ID NO:36) Example 35: [Aib17, 4Hyp34, Aic36]hNPY(l-36)-NH2; (SEQ ID NO:37)
Example 36: [Aib17, 4Hyp34, 4NH2Phe35]hNPY(l-36)-NH2; (SEQ ID NO:38)
Example 37: [Aib17, 4Hyp34, 4NH2CH2Phe35]hNPY( 1-3 O)-NH2; (SEQ ID NO:39)
Example 38: [Aib17, 4Hyp34, Lys35-ψ(CH2-NH)Tyr36]hNPY(l-36)-NH2; (SEQ ID NO:40)
Example 39: [Aib11'17, 4Hyp34, Lys35-ψ(CH2-NH)Tyr36]hNPY(l-36)-NH2; (SEQ ID NO:41) Example 40: [Nip34]hNPY( 1-3 O)-NH2; (SEQ ID NO:42)
Example 41 : [Inp34]hNPY(l-36)-NH2; (SEQ ID NO:43)
Example 42: [Dhp34]hNPY(l-36)-NH2; (SEQ ID NO:44)
Example 43: [hPro34]hNPY(l-36)-NH2; (SEQ ID NO:45)
Example 44: [Tic34]hNPY(l-36)-NH2; and (SEQ ID NO:46) Example 45: [Leu31, Lys34(Nε-C(O)-(CH2)i2-CH3)]hNPY(l-36)-NH2. (SEQ ID NO:47)
DETAILED DESCRIPTION OF THE INVENTION
As used herein the term "amino acid" refers to any natural or unnatural amino acid, including but not limited to α-amino acids, β-amino acids, or γ-amino acids, and may be either D- or L-amino acid unless otherwise indicated.
With the exception of the N-terminal amino acid, all amino acid abbreviations (e.g., Ala) in this disclosure have the structure -NH-C(R)(R')-CO-, wherein R and R1 each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH3 and R' = H for Ala), or R and R' may be joined to form a ring system. For the N-terminal amino acid, the abbreviation stands for the structure of (R2R3)-N-C(R)(R')-CO-, wherein R2 and R3 are as defined in the formula (I).
A peptide of this invention is also denoted by another format, e.g., [Pro34] hNP Y(I- 36)-NH2 (SEQ ID NO:48), with the substituted amino acids from the natural sequence placed between the brackets, e.g. , Pro for GIn in hNPY. The designation "NH2" in hNPY( 1 -36)- NH2 (SEQ TD NO:1) indicates that the C-terminus of the peptide is amidated whereas hNPY(l-36)-OH (SEQ ID NO:49) indicates the free acid form.
The following list of some of the abbreviations used in the present application is provided for ease of reference, however, any abbreviation used in the instant application not defined herein are not used contrary to the recognized meanings thereof.
Abu α-aminobutyric acid
Ace 1 -amino- l-cyclo(C3-9)alkyl carboxylic acid, wherein
A3c represents 1 -amino- 1-cyclopropanecarboxylic acid; A4c represents 1 -amino- 1-cyclobutanecarboxylic acid;
A5c represents 1 -amino- 1-cyclopentanecarboxylic acid; and A6c represents 1 -amino- 1-cyclohexanecarboxylic acid
Adc 10-aminodecanoic acid
Ado 12-aminododecanoic acid Ahp 7-aminoheptanoic acid
Ahx 6-aminohexanoic acid
Aib α-aminoisobutyric acid
Aic 2-aminoindan-2 -carboxylic acid
Ala or A alanine Anc 9-aminononanoic acid
Aoc 8-aminooctanoic acid
Ape 4-amino-4-carboxypiperidine, represented by structure:
Figure imgf000010_0001
wherein, the parallel lines "— " indicate points of attachment of the moiety to another moiety or sequence.
Apn 5-aminopentanoic acid
Arg or R arginine hArg homoarginine
Asn or N asparagine Asp or D aspartic acid
Aun 11-aminoundecanoic acid
Cha β-cyclohexylalanine
Cys or C cysteine
Dab 2,4-diaminobutyric acid
Dap 2,3-diaminopropionic acid
Dhp 3 ,4-dehydroproline
Dmt 5,5-dimethylthiazolidine-4-carboxylic acid
Gaba 4-aminobutyric acid
GGIInn oorr QQ glutamine
GIu or E glutamic acid
GIy or G glycine
His or H histidine
3Hyp trans-3-hydroxy-L-proline, i.e., (2S, 3S)-3-hydroxypyrrolidine-2- carboxylic acid cis-3Hyp cis-3-hydroxy-L-proline, i.e., (2S, 3R)-3-hydroxypyrrolidine-2- carboxylic acid 4Hyp 4-hydroxyproline, i.e., (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid cis-4Hyp cis-4-hydroxy-L-proline, i.e., (2S, 4S)-4-hydroxypyrrolidine-2- carboxylic acid He or I isoleucine
Inc indoline-2-carboxylic acid
Inp isonipecotic acid Ktp 4-ketoproline
Leu or L leucine hLeu homoleucine
Lys or K lysine Met or M methionine Nip nipecotic acid
NIe norleucine
N8 indicates that the entity within the parentheses is coupled to the epsilon-nitrogen of the Lys sidechain Nva norvaline Oic octahydroindole-2-carboxylic acid
Om ornithine
2-Pal β-(2-pyridyl)alanine
3-Pal β-(3 -pyridyl)alanine
4-Pal β-(4-pyridyl)alanine
Phe or F phenylalanine hPhe homophenylalanine
4NH2CH2Phe 4-aminomethyl-phenylalanine
4NH2Phe 4-amino-phenylalanine
Pro or P proline hPro homoproline
Sar sarcosine or N-methyl glycine
Ser or S serine
Thr or T threonine
Tic 1 ,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Tie tert-leucine
VaI or V valine
Certain other abbreviations used herein are defined as follows:
Ac acetyl
Aloe allyloxycarbonyl
Boc tert-butyloxycarbonyl
Bhoc benzhydryloxycarbonyl
BSA bovine serum albumin
BzI benzyl
DCM dichloromethane
Dde 1 -(4,4-dimethyl-2,6-dioxocyclohex- 1 -ylidine)ethyl
DIC N, N-diisopropylcarbodiimide
DIEA: diisopropylethyl amine
Dmab 4- {N-( 1 -(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)- amino} benzyl
DMAP 4-(dimethylamino)pyridine
DMF dimethylformamide
DNP 2,4-dinitrophenyl
EMEM Eagle's minimal essential medium et ethyl
Fmoc fluorenylmethyloxycarbonyl
HATU O-(7-azabenzotriazole- 1 -yl)- 1 , 1 ,3,3-tetramethyluronium hexafluorophosphate
HBTU 2-( 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate cHex cyclohexyl HOAT O-(7-azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate
HOBt 1 -hydroxy-benzotriazole
HPLC high performance liquid chromatography
MBHA 4-methylbenzhydrylamine
Mmt 4-methoxytrityl
NMP N-methyl-2-pyrrolidinone
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl tBu tert-butyl
TIS triisopropylsilane
TOS tosyl
Trt trityl
TFA trifluoro acetic acid
TFFH tetramethylfluoroforamidinium hexafluorophosphate
Lys-ψ(CH2 -NH)Tyr has the structure of:
Figure imgf000013_0001
The Greek letter psi "ψ" is used herein to indicate that a peptide bond has been replaced by a pseudopeptide bond. In an amino acid sequence name, the format of the ψ term is A-ψ(X-X')-B wherein A is the amino acyl radical whose carbonyl group has been modified to X and B the amino acyl radical whose α-amino groups has been modified to X'. X and X' are shown as strings of element symbols, separated by a bond, e.g., Lys-ψ(CH2-NH)-Tyr.
"Alkyl" refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds, examples of which include but are not limited to methyl, ethyl, propyl and butyl. The alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups, examples of which include, but are not limited to, isopropyl and tertbutyl.
"Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH2, NHCH3, NO2, (C1-2) alkyl substituted with 1 to 6 halogens, CF3, OCH3, OCF3, and (CH2)0-4-COOH. In different embodiments, 1, 2, 3 or 4 substituents are present. The presence of (CH2)O-4-COOH results in the production of an alkyl acid. Examples of alkyl acids containing (CH2)O-4-COOH include, but are not limited to, 2-norbornane acetic acid, tert-butyric acid and 3-cyclopentyl propionic acid.
"Heteroalkyl" refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group are replaced with one or more of the following atoms or groups: amino, amido, O, S, N, and carbonyl. hi different embodiments, 1 or 2 heteroatoms are present.
"Substituted heteroalkyl" refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH2, NHCH3, NO2, (C1-2) alkyl substituted with 1 to 6 halogens, CF3, OCH3, OCF3, and (CH2)O-4-COOH. hi different embodiments, 1, 2, 3 or 4 substituents are present.
"Alkenyl" refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present, examples of which include, but are not limited to, vinyl, allyl, butenyl and propenyl. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups, examples of which include, but are not limited to, n-butenyl versus t-butenyl, and n-pentenyl compared to cyclopentenyl.
"Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH2, NHCH3, NO2, (C1-2) alkyl substituted with 1 to 6 halogens, CF3, OCH3, OCF3, and (CH2)0-4-COOH. In different embodiments, 1, 2, 3 or 4 substituents are present.
"Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated π-electron system containing up to two conjugated or fused ring systems. Aryl includes, but is not limited to, carboxylic aryl, heterocyclic aryl and biaryl groups. Preferably, an aryl is a 5- or 6-membered ring. Preferred atoms for a heterocyclic aryl include, but are not limited to, one or more of sulfur, oxygen and nitrogen. Examples of aryl include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and 9-anthracene. Aryl substituents are selected from the group consisting Of(Ci-4) alkyl, (C1-4) alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), OH, CN, SH, NH2, NO2, (C1-2) alkyl substituted with 1 to 5 halogens, CF3, OCF3, and (CH2)0-4-COOH. In different embodiments, aryl contains O, 1, 2, 3 or 4 substituents.
"Alkylaryl" refers to an "alkyl" joined to an "aryl," as defined above.
The term "cycloalkyl" is intended to include a mono-cycloalkyl group or a bi- cycloalkyl group of the indicated carbon number known to those of skill in the art.
The term "heterocycle" includes mono-cyclic and bi-cyclic systems having one or more heteroatoms, such as oxygen, nitrogen and sulfur. The ring systems may be aromatic, for example, pyridine, indole, quinoline, pyrimidine, thiophene (also known as thienyl), furan, benzothiophene, tetrazole, dihydroindole, indazole, N-formylindole, benzimidazole, thiazole, and thiadiazole. The ring systems also may be non-aromatic, for example, but not limited to, pyrrolidine, piperidine, morpholine, and the like.
Synthesis
The compounds of this invention can be and were produced using the techniques disclosed in the examples herein as well as techniques that are well known in the art. For example, a polypeptide region of an NPY analogue can be chemically or biochemically synthesized and/or modified. See, e.g., Stewart, J. M., et al, Solid Phase Synthesis, Pierce Chemical Co., 2d ed. (1984); and see, e.g., Sambrook et al, Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press (1989) for examples of techniques for biochemical synthesis involving the introduction of a nucleic acid into a cell and expression of nucleic acids.
The examples are provided for the purpose of illustration and are not meant to limit the scope of the present invention in any manner. Example 1: TAib10. 4Hvp341hNPY(l-36VNH2
The titled peptide was assembled using Fmoc-chemistry. The C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale. The reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 minutes to swell the resin. The ABI FastMoc 1.0® protocol was used to generate the peptide.
Each cycle comprised of deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing. Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBT/HBTU. After enough time was allotted for dissolution of the amino acid, it was automatically transferred to the activation vessel. Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step. DIPEA, 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
This entire mixture was then introduced to the resin and allowed to mix for 15 minutes. The reaction vessel was emptied, washed with NMP and then followed by a second coupling step. Following the second coupling step, the resin was again thoroughly washed. Each amino acid was double-coupled in a similar fashion. Following the coupling step of the first Tyr residue, for each of the next 4 coupling steps, and each Arg coupling step, the resin was capped with 5 ml of capping solution (0.5M acetic anhydride / 0.13M DIPEA / 0.01M HOBT) to block any unacylated resin sites. The following amino acid cartridges were used for the coupling steps: Cycle 1) Fmoc-Tyr(tBu)-OH; Cycle 2) Fmoc-Arg(Pbf)-OH; Cycle 3) Fmoc-4Hyp-OH; Cycle 4) Fmoc-Arg(Pbf)-OH; Cycle 5) Fmoc-Thr(tBu)-OH; Cycle 6) Fmoc-Ile-OH; Cycle 7) Fmoc-Leu-OH; Cycle 8) Fmoc-Asn(Trt)-OH; Cycle 9) Fmoc-Ile- OH; Cycle 10) Fmoc-Tyr(tBu)-OH; Cycle 11) Fmoc-His(Trt)-OH; Cycle 12) Fmoc- Arg(Pbf)-OH; Cycle 13) Fmoc-Leu-OH; Cycle 14) Fmoc-Ala-OH; Cycle 15) Fmoc- Ser(tBu)-OH; Cycle 16) Fmoc-Tyr(tBu)-OH; Cycle 17) Fmoc-Tyr(tBu)-OH; Cycle 18) Fmoc-Arg(Pbf)-OH; and Cycle 19) Fmoc-Ala-OH. Following the last coupling cycle, the resin was washed with NMP, followed by standard N-terminal Fmoc deblocking, washed with NMP followed by DCM.
Following assembly of the C-terminal portion of the peptide backbone (residues 18- 36), only one tenth of the resin (0.1 mmole) was used to construct the N-terminal portion of the peptide, with the remainder saved. The N-terminal portion of the titled peptide (residues 1-17) was constructed using microwave-assisted Fmoc Chemistry on Liberty Peptide Synthesizer (CEM, Matthews, NC, USA) at the 0.1 mmole scale. The resin from the previous synthesis was placed in a 50 ml conical tube along with 15 ml of DMF and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process. The standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine, containing 0.1M HOBT, in DMF. The initial deprotection step was for 30 seconds with microwave power (45 watts, maximum temperature of 75 0C), and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment, except that it was for a 3 -minute duration.
The resin was then drained and thoroughly washed with DMF several times. The protected amino acid, Fmoc-Met-OH, prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 equivalents), followed by 1.0 ml of 0.45M (4.5 eq.) HBTU in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA in NMP. The coupling step was performed for 5 minutes using 20 watts of microwave power, a maximum temperature of 75 0C, and the same rate of nitrogen bubbling. Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated. Cycle 2 was then initiated similar to Cycle 1. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Residues 9-10 (GIy- Aib) contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride, containing 0.015M HOBT in NMP, along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0C maximum temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF. The following amino acids (Advanced Chemtech, Louisville, KY, USA) were used: Cycle 20) Fmoc-Met-OH; Cycle 21) Fmoc- Asp(OtBu)-OH; Cycle 22) Fmoc-Glu(OtBu)-OH; Cycle 23) Fmoc-Ala-OH; Cycle 24) Fmoc- Pro-OH; Cycle 25) Fmoc-Ala-OH; Cycle 26) Fmoc-Asp(OtBu)-OH; Cycle 27) Fmoc-Aib- OH; Cycle 28) Fmoc-Gly-OH; Cycle 29) Fmoc-Pro-OH; Cycle 30) Fmoc-Asn(Trt)-OH; Cycle 31) Fmoc-Asp(OtBu)-OH; Cycle 32) Fmoc-Pro-OH; Cycle 33) Fmoc-Lys(Boc)-OH; Cycle 34) Fmoc-Ser(tBu)-OH; Cycle 35) Fmoc-Pro-OH; Cycle 36) Fmoc-Tyr(tBu)-OH.
Once the peptide backbone was complete, standard piperidine treatment was used to remove the N-terminal Fmoc group using the standard deprotection procedure described previously. The resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
The resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours. The filtrate was collected into 45 ml of cold anhydrous ethyl ether. The precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge. The ether was decanted and the peptide re-suspended in fresh ether. The ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether. The peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve. The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 4212.1, corresponding to the desired product. Analytical HPLC analysis, employing a 250 x 4.6 mm Cl 8 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes, identified a main product with 45% purity. The crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate. The purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4212.8 da), with the experimental mass corresponding well to the expected mass of 4212.7. The peptide was subsequently lyophilized producing 39 mg of purified product representing a 9% yield.
Example 2: [Aib17. 4Hyp34lhNPY(l-36VNH7
The titled peptide was assembled using Fmoc-chemistry. The C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale. The reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 minutes to swell the resin. The ABI FastMoc 1.0® protocol was used to generate the peptide. Each cycle comprised deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing. Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBTVHBTU. After the amino acid had dissolved, it was automatically transferred to the activation vessel. Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step. DIPEA, 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
This entire mixture was then introduced to the resin and allowed to mix for 15 minutes. The reaction vessel was emptied, washed with NMP, and then followed by a second coupling step. Following the second coupling step, the resin was again thoroughly washed. Each amino acid was double-coupled in a similar fashion. Following the coupling step of the first Tyr residue, for each of the next four coupling steps and each Arg coupling step, the resin was capped with 5 ml of capping solution (0.5M acetic anhydride / 0.13M DIPEA / 0.0 IM HOBT) to block any unacylated resin sites. The following amino acid cartridges were used for the coupling steps: Cycle 1) Fmoc-Tyr(tBu)-OH; Cycle 2) Fmoc-Arg(Pbf)-OH;
Cycle 3) Fmoc-4Hyp-OH; Cycle 4) Fmoc-Arg(Pbf)-OH; Cycle 5) Fmoc-Thr(tBu)-OH; Cycle 6) Fmoc-Ile-OH; Cycle 7) Fmoc-Leu-OH; Cycle 8) Fmoc-Asn(Trt)-OH; Cycle 9) Fmoc-Ile- OH; Cycle 10) Fmoc-Tyr(tBu)-OH; Cycle 11) Fmoc-His(Trt)-OH; Cycle 12) Fmoc- Arg(Pbf)-OH; Cycle 13) Fmoc-Leu-OH; Cycle 14) Fmoc- AIa-OH; Cycle 15) Fmoc- Ser(tBu)-OH; Cycle 16) Fmoc-Tyr(tBu)-OH; Cycle 17) Fmoc-Tyr(tBu)-OH; Cycle 18) Fmoc-Arg(Pbf)-OH; and Cycle 19) Fmoc- AIa-OH.
Following the last coupling cycle, the resin was washed with NMP, followed by standard N-terminal Fmoc deblocking and washed with NMP followed by DCM. After assemblying the C-terminal portion of the peptide backbone (residues 18-36), one tenth of the resin (0.1 mmole) was used to construct the N-terminal portion of the peptide, with the remainder conserved. The N-terminal portion of the titled peptide (residues 1-17) was constructed using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM, Matthews, NC, USA) at the 0.1 mmole scale. The resin from the previous synthesis was placed in a 50 ml conical tube along with 15 ml of DMF and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process. The standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used involving deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine containing 0.1M HOBT in DMF. The initial deprotection step lasted 30 seconds with microwave power (45 watts, maximum temperature of 75 0C) and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment was applied for 3 minutes. The resin was then drained and thoroughly washed with DMF several times. The protected amino acid, Fmoc-Aib-OH prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 equivalents) followed by 1.0 ml of 0.45M (4.5 eq.) HBTU in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA in NMP. The coupling step was performed for 5 minutes using 20 watts of microwave power, at a maximum temperature of 75 0C, and the same rate of nitrogen bubbling. Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated.
Cycle 2 which was similar to Cycle 1 was then initiated. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire sequence. Residues 16-17 (Asp-Aib) contained a capping procedure immediately following the coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride containing 0.015M HOBT in NMP along with 2 ml of the 2M DIPEA solution using a multi- step microwave protocol: 50 watts of power for 30 seconds (65 0C maximum temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF. The following amino acids (Advanced Chemtech, Louisville, KY, USA) were used: Cycle 20) Fmoc-Aib-OH; Cycle 21) Fmoc-Asp(OtBu)-OH; Cycle 22) Fmoc-Glu(OtBu)-OH; Cycle 23) Fmoc-Ala-OH; Cycle 24) Fmoc-Pro-OH; Cycle 25) Fmoc-Ala-OH; Cycle 26) Fmoc-Asp(OtBu)-OH; Cycle 27) Fmoc- GIu(OtBu)-OH; Cycle 28) Fmoc-Gly-OH; Cycle 29) Fmoc-Pro-OH; Cycle 30) Fmoc- Asn(Trt)-OH; Cycle 31) Fmoc-Asp(OtBu)-OH; Cycle 32) Fmoc-Pro-OH; Cycle 33) Fmoc- Lys(Boc)-OH; Cycle 34) Fmoc-Ser(tBu)-OH; Cycle 35) Fmoc-Pro-OH; and Cycle 36) Fmoc- Tyr(tBu)-OH.
Once the peptide backbone was complete, standard piperidine treatment was used to remove the N-terminal Fmoc group using the standard deprotection procedure described previously. The resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
The resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours. The filtrate was collected into 45 ml of cold anhydrous ethyl ether. The precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge. The ether was decanted and the peptide re-suspended in fresh ether. The ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether. The peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve.
The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 4210.8, corresponding to the desired product. Analytical HPLC analysis, employing a 250 x 4.6 mm Cl 8 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes, identified a main product with 54% purity. The crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate. The purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4210.6 da) with the experimental mass corresponding to the expected mass of 4210.6. The peptide was subsequently lyophilized producing 53 mg of purified product representing a 13% yield.
Example 3: fAib11'17. 4HvP34IhNPY(I -36VNH7
The titled peptide was assembled using Fmoc-chemistry. The C-terminal portion of the peptide (residues 18-36) was synthesized on ABI 433 A Peptide Synthesizer (Applied Biosystems, Foster City, CA, USA) at the 1.0 mmole scale. The reaction vessel containing 1.37 g of 0.73 mmol / Rink Amide MBHA resin (Novabiochem, San Diego, CA, USA) was placed in a reaction vessel. The resin was then treated with 10 ml of NMP for 15 min to swell the resin. The ABI FastMoc 1.0® protocol was used to generate the peptide.
Each cycle was comprised of deblocking the N-terminal Fmoc using 20% piperidine followed by extensive NMP washing. Pre-packaged 1.0 mmole cartridges of each amino acid were then dissolved in 0.45M HOBT/HBTU. After the amino acid had dissolved, it was automatically transferred to the activation vessel. Two more 1.0 mmole amino acid cartridges were dissolved and transferred to the activation vessel for a total of 3 equivalents of amino acid used per coupling step. DEPEA, 3 ml of a 2M solution, was then introduced to the activation vessel for a total of 6 eq. DIPEA.
This entire mixture was then introduced to the resin and allowed to mix for 15 minutes. The reaction vessel was emptied, washed with NMP, and then followed by a second coupling step. Following the second coupling step, the resin was again thoroughly washed. Each amino acid was double-coupled in a similar fashion. Following the coupling step of the first Tyr residue, for each of the next 4 coupling steps and each Arg coupling step, the resin was capped with 5 ml of capping solution (0.5M acetic anhydride / 0.13M DIPEA / 0.01M HOBT) to block any unacylated resin sites. The following amino acid cartridges were used for the coupling steps: Cycle 1) Fmoc-Tyr(tBu)-OH; Cycle 2) Fmoc-Arg(Pbf)-OH; Cycle 3) Fmoc-4Hyp-OH; Cycle 4) Fmoc-Arg(Pbf)-OH; Cycle 5) Fmoc-Thr(tBu)-OH; Cycle 6) Fmoc-Ile-OH; Cycle 7) Fmoc-Leu-OH; Cycle 8) Fmoc-Asn(Trt)-OH; Cycle 9) Fmoc-Ile- OH; Cycle 10) Fmoc-Tyr(tBu)-OH; Cycle 11) Fmoc-His(Trt)-OH; Cycle 12) Fmoc- Arg(Pbf)-OH; Cycle 13) Fmoc-Leu-OH; Cycle 14) Fmoc- AIa-OH; Cycle 15) Fmoc- Ser(tBu)-OH; Cycle 16) Fmoc-Tyr(tBu)-OH; Cycle 17) Fmoc-Tyr(tBu)-OH; Cycle 18) Fmoc-Arg(Pbf)-OH; and Cycle 19) Fmoc- AIa-OH. Following the last coupling cycle, the resin was washed with NMP, deblocked by standard N-terminal Fmoc deblocking, and again washed with NMP followed by DCM.
Following assembly of the C-terminal portion of the peptide backbone (residues 18- 36), only one tenth of the resin (0.1 mmole) was used to construct the N-terminal portion of the peptide with the remainder saved. The N-terminal portion of the titled peptide (residues 1-17) was constructed using microwave-assisted Fmoc Chemistry on a Liberty Peptide Synthesizer (CEM, Matthews, NC, USA) at the 0.1 mmole scale. The resin from the previous synthesis was placed in a 50 ml conical tube along with 15ml of DMF and loaded onto a resin position on the synthesizer. The resin was then quantitatively transferred to the reaction vessel via the automated process. The standard Liberty synthesis protocol for 0.1 mmole scale synthesis was used. This protocol involves deprotecting the N-terminal Fmoc moiety via an initial treatment with 7 ml of 20% piperidine containing 0.1M HOBT in DMF. The initial deprotection step lasted 30 seconds with microwave power (45 watts, maximum temperature of 75 0C) and nitrogen bubbling (3 seconds on / 7 seconds off). The reaction vessel was then drained and a second piperidine treatment, identical to the first treatment except that it was for a 3-minute duration was applied. The resin was then drained and thoroughly washed with DMF several times. The protected amino acid, Fmoc-Aib-OH prepared as 0.2M stock solution in DMF, was then added (2.5 ml, 5 equivalents) followed by 1.0 ml of 0.45M (4.5 eq.) HBTU in DMF. This was followed by the addition of 0.5 ml of 2M (10 eq.) DIPEA in NMP. The coupling step was performed for 5 minutes using 20 watts of microwave power at a maximum temperature of 75 0C and the same rate of nitrogen bubbling. Following the initial coupling step, the reaction vessel was drained to waste and the coupling step repeated.
Cycle 2 which was similar to Cycle 1 was then initiated. All amino acids were introduced similarly and a double-coupling strategy was employed throughout the entire process. Residues 10-11 and 16-17 (GIu- Aib and Asp-Aib) contained a capping procedure immediately following each coupling step. Capping was performed by adding 7 ml of 0.5M acetic anhydride containing 0.015M HOBT in NMP along with 2 ml of the 2M DIPEA solution using a multi-step microwave protocol: 50 watts of power for 30 seconds (65 0C max temperature), followed by 30 seconds of microwave power off, followed by a second round of 30 seconds of microwave power on (50 watts), and then again 30 seconds of no microwave power. The resin was then drained and thoroughly washed with DMF. The following amino acids (Advanced Chemtech, Louisville, KY, USA) were used: Cycle 20) Fmoc-Aib-OH; Cycle 21) Fmoc-Asp(OtBu)-OH; Cycle 22) Fmoc-Glu(OtBu)-OH; Cycle 23) Fmoc-Ala-OH; Cycle 24) Fmoc-Pro-OH; Cycle 25) Fmoc-Ala-OH; Cycle 26) Fmoc-Aib- OH; Cycle 27) Fmoc-Glu(OtBu)-OH; Cycle 28) Fmoc-Gly-OH; Cycle 29) Fmoc-Pro-OH; Cycle 30) Fmoc-Asn(Trt)-OH; Cycle 31) Fmoc-Asp(OtBu)-OH; Cycle 32) Fmoc-Pro-OH; Cycle 33) Fmoc-Lys(Boc)-OH; Cycle 34) Fmoc-Ser(tBu)-OH; Cycle 35) Fmoc-Pro-OH; and Cycle 36) Fmoc-Tyr(tBu)-OH.
Once the peptide backbone was complete, a standard piperidine treatment was used to remove the N-terminal Fmoc group using the standard deprotection procedure described previously. The resin was then thoroughly washed with DMF and then transferred back to the 50 ml conical tube using DMF as the transfer solvent.
The resin was deprotected and cleaved from the resin via treatment with 5 ml of the following reagent: 5% TIS, 2% water, 5% (w/v) DTT, and 88% TFA, and allowed to mix for 3.5 hours. The filtrate was collected into 45ml of cold anhydrous ethyl ether. The precipitate was pelleted for 10 minutes at 3500 RPM in a refrigerated centrifuge. The ether was decanted and the peptide re-suspended in fresh ether. The ether workup was performed a total of 2 times. Following the last ether wash, the peptide was allowed to air dry to remove residual ether. The peptide pellet was resuspended in 8 ml of acetonitrile followed by 8 ml of de-ionized water and allowed to fully dissolve.
The peptide solution was then analyzed by mass spectrometry. Mass analysis employing electrospray ionization identified a main product containing a mass of 4180.7, corresponding to the desired product. Analytical HPLC analysis, employing a 250 x 4.6 mm C18 column (Phenomenex, Torrance, CA, USA) using a gradient of 2-60% acetonitrile (0.1% TFA) over 30 minutes identified a main product with 68% purity. The crude peptide was then purified on a preparative HPLC equipped with a Cl 8 reverse phase column using a 10- 60% acetonitrile (0.1% TFA) over 50 minutes at a 10 ml/min flow rate. The purified product was analyzed by HPLC for purity (>99%) and mass spectrometry (4180.5 da), with the experimental mass corresponding to the expected mass of 4180.6. The peptide was subsequently lyophilized producing 53 mg of purified product representing a 13% yield.
Other compounds of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed in the foregoing examples. Physical data for the compounds exemplified herein are given in Table 1.
TABLE l
Figure imgf000024_0001
Figure imgf000025_0001
Human neuroblastoma cell lines, SK-N-MC and SK-N-BE2 (American Type Culture Collection, Rockville, MD, USA), expressing the NPY-Yl and NPY-Y2 receptors, respectifully, were cultured in EMEM containing 10% fetal calf serum and 5% chicken embryo extract, and maintained at 37 °C in a humidifed atmosphere of and 95% air and 5% CO2.
For the in vitro NPY-Yl and NPY-Y2 radioligand binding assays, the appropriate cells (SK-N-MC for NPY-Yl; SK-N-BE2 for NPY- Y2) were harvested, homogenized in 20 ml of ice-cold 50 mM Tris-HCl with a Brinkman Polytron (Westbury, NY, USA) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were resuspended in 50 mM Tris-HCl, containing 2.5 mM MgCl2, 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO, USA), and 0.1% BSA.
For assay, aliquots (0.4 ml) of the foregoing suspensions were incubated with 0.05 nM [125qPYY (2200 Ci/mmol, Perkin-Elmer, Boston, MA), with and without 0.05 ml of unlabeled competing test peptides. After a 100 min incubation (25 °C), the bound [125I]PYY was separated from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, MD, USA), which had been previously soaked in 0.3% polyethyleneimine. The filters were then washed three times with 5-ml aliquots of ice-cold 50 mM Tris-HCl, and the bound radioactivity trapped on the filters was counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD, USA). Specific binding was defined as the total [125I]PYY bound minus that bound in the presence of 1000 nM PYY (Bachem, Torrence, CA, USA). Inhibition constants (Ki) were calculated using the well-known Cheng-Prusoff equation, and said data, together with selectivity of said compounds with respect to the NPY-Yl and the NPY- Y2, are given in Table 2.
Each of the compounds of Examples 1-38 and 40-45 was subjected to the immediately foregoing radioligand assays, and nearly all of said compounds were found to have Ki of under 100 nM, as well as some of the exemplified compounds having Ki values in sub-nM range. It was also found that nearly all of said compounds highly selectively bind to the NPY-Yl compared to the NPY- Y2.
TABLE 2
Figure imgf000026_0001
Figure imgf000027_0001
Administration
The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1) 0. IN ammonium acetate aqueous solution for 0.5 hours, (2) 0.25N acetic acid aqueous solution for 0.5 hours, and (3) a linear gradient (20% to 100% of solution B over 30 min) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness. The dosage of active ingredient in the compositions of this invention may be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, the route of administration, and the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1 x 10"7 to 200 mg/kg/day, preferably 1 x 10"4 to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.
The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration, and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration include, without limitation, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
Preparations according to this invention for parenteral administration include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, emulsions, and the like. Examples of non-aqueous solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtering through a bacteria-retaining filter, incorporating sterilizing agents, irradiating, or heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium, immediately before use. Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Patent No.5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. PCT publication WO99/38536 teaches absorbable sustained release compositions of a bioactive agent. PCT publication WO00/04916 teaches a process for making microparticles comprising a therapeutic agent such as a peptide in an oil-in-water process. PCT publication WO00/09166 teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer. PCT publication WO00/25826 teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non- polymerizable lactone. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are hereby incorporated by reference, each in its entirety.

Claims

CLAIMSWhat is claimed is:
1. A compound according to formula (I) (SEQ DD NO: 2):
(R^^-A^A^A^A"-^^-^-^^^10^''^^^13^'^^^^^17^^^^-^0-
A21.A22_A23.A24.A25.A26.A27.A28.A29.A30.A31.A32.A33.A34.A35.A36.A37.Rl
(I) wherein: A1 is Tyr, (X1 ,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A2 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A3 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH2)n-N(R4R5))-C(O);
A4 is Lys, Arg, hArg, Dab, Dap, Orn, or HN-CH((CH2)n-N(R4R5))-C(O);
A5 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp; A6 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A7 is Asn, Aib, GIn, or HN-CH((CH2)n-N(R4R5))-C(O);
A8 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A9 is GIy, Aib, or HN-CH((CH2)n-N(R4R5))-C(O);
A10 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH2)n-N(R4R5))-C(O); A1 ' is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A12 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A13 is Pro, 3Hyp, cis-3Hyp, 4Hyp, or cis-4Hyp;
A14 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A15 is GIu, Aib, Asn, Asp, GIn, or HN-CH((CH2)n-N(R4R5))-C(O); A16 is Asp, Aib, Asn, GIn, GIu, or HN-CH((CH2)n-N(R4R5))-C(O);
A17 is Met, Ace, Aib, Cha, He, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A18 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A19 is Arg, hArg, Ape, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O); A20 is Tyr, (X1 ,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A21 is Tyr, (X',X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A22 is Ser, Abu, Aib, Ala, Thr, or HN-CH((CH2)n-N(R4R5))-C(O);
A23 is Ala, Abu, Aib, Nva, VaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A24 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))- C(O); A25 is Arg, hArg, Dab, Dap, Lys, Om, or HN-CH((CH2)n-N(R4R5))-C(O);
A26 is His, 2PaI, 3PaI, 4PaI, or HN-CH((CH2)n-N(R4R5))-C(O);
A27 is Tyr, (X1,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A28 is He, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))- C(O);
A29 is Asn, Aib, GIn, or HN-CH((CH2)n-N(R4R5))-C(O);
A30 is Leu, Ace, Cha, He, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))-
C(O);
A31 is He, Ace, Cha, Leu, hLeu, NIe, Nva, Tie, VaI, or HN-CH((CH2)n-N(R4R5))- C(O);
A32 is Thr, Aib, Ser, or HN-CH((CH2)n-N(R4R5))-C(O);
A33 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O);
A34 is GIn, Asn, Dhp, 3Hyp, cis-3Hyp, 4Hyp, cis-4Hyp, Inp, Ktp, Nip, Oic, hPro, Tic, or HN-CH((CH2)n-N(R4R5))-C(O); A35 is Arg, Aic, Ape, hArg, Dab, Dap, Lys, Orn, NH2Phe, NH2CH2Phe, or
HN-CH((CH2)n-N(R4R5))-C(O);
A36 is Tyr, Aic, (X1,X2,X3,X4,X5)Phe, or HN-CH((CH2)n-N(R4R5))-C(O);
A37 is HN-CH((CH2)n-N(R4R5))-C(O) or deleted;
R1 is OH, NH2, (Ci-30)alkoxy, or NH-X6-CH2-X7, wherein X6 is a (C1-40)alkyl or (C2- 40)alkenyl, and wherein X7 is H, OH, CO2H, or C(O)-NH2;
R2 and R3 each is, independently for each occurrence, selected from the group consisting of H, (Ci-30)alkyl, (C1-3o)heteroalkyl, (C1-30)acyl, (C2-30)alkenyl, (C2-30)alkynyl, aryl(C1-30)alkyl, aryl(Ci-3o)acyl, substituted (C1-3o)alkyl, substituted (Ci-30)heteroalkyl, substituted (C2-3o)acyl, substituted (C2-3o)alkenyl, substituted (C2-3o)alkynyl, substituted aryl(C1-3o)alkyl, and substituted aryl(C1-3o)acyl; provided that when R2 is (C1-3o)acyl, aryl(C1-3o)acyl, substituted (C2-30)acyl, or substituted aryl(C1-30)acyl, R3 is H, (C1-3o)alkyl, (Ci-3o)heteroalkyl, (C2-3o)alkenyl, (C2- 3o)alkynyl, aryl(Ci-3o)alkyl, substituted (C1-3o)alkyl, substituted (C1-3o)heteroalkyl, substituted (C2-30)alkenyl, substituted (C2-3o)alkynyl, or substituted aryl(C1-3o)alkyl; R4 and R5 each is, independently for each occurrence, H, (Ci-40)alkyl, (Ci-
4o)heteroalkyl, (Ci-4o)acyl, (C2-4o)alkenyl, (C2-4o)alkynyl, aryl(C1-4o)alkyl, aryl(C1-4o)acyl, substituted (d-4o)alkyl, substituted (CMo)heteroalkyl, substituted (Ci-40)acyl, substituted (C2- 4θ)alkenyl, substituted (C2-4o)alkynyl, substituted aryl(Ci-4o)alkyl, substituted aryl(C1-4o)acyl, (Ci-4o)alkylsulfonyl, or C(NH)-NH2, wherein when R4 is (Ci^acyl, aryl(Ci-4o)acyl, substituted (C1-40)ECyI, substituted aryl(Ci-4o)acyl, (C1-40)alkylsulfonyl, or C(NH)-NH2, then R5 is H or (CrC4o)alkyl, (C1-40)heteroalkyl, (C2-40)alkenyl, (C2-40)alkynyl, aryl(C1-4o)alkyl, substituted (Ci-4o)alkyl, substituted (CM0)heteroalkyl, substituted (C2-4o)alkenyl, substituted (C2-4o)alkynyl, or substituted aryl(d _40)alkyl; n is, independently for each occurrence, 1, 2, 3, 4, or 5;
X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, F, Cl, Br, I, (Ci- 10)alkyl, substituted (C1-10)alkyl, aryl, substituted aryl, OH, CH2NH2, NH2, NO2, or CN; and provided that the compound contains at least one substitution with an unnatural amino acid; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein:
A1 is Tyr;
A2 is Pro; A3 is Ser or Aib;
A4 is Lys;
A5 is Pro;
A6 is Asp or Aib;
A7 is Asn or Aib; A8 is Pro;
A9 is GIy or Aib;
A10 is GIu or Aib;
A11 is Asp or Aib;
A12 is Ala or Aib; A13 is Pro;
A14 is Ala or Aib;
A15 is GIu or Aib;
A16 is Asp or Aib;
A17 is Met, A6c, Aib, or NIe; A18 is Ala or Aib;
A19 is Arg;
A20 is Tyr;
A21 Tyr;
A22 is Ser or Aib; A23 is Ala or Aib;
A24 is Leu or A6c;
A25 is Arg;
A26 is His; A27 is Tyr;
A28 is He or A6c;
A29 is Asn or Aib;
A30 is Leu or A6c;
A31 is He, A6c, or Leu; A32 is Thr or Aib;
A33 is Arg;
A34 is Dhp, 4Hyp, Inp, Nip, hPro, Tic, or HN-CH((CH2)n-N(R4R5))-C(O);
A35 is Arg, Ape, Lys, 4NH2Phe, or 4NH2CH2Phe;
A36 is Tyr or Aic; A37 is deleted;
R1 is NH2;
R2 and R3 each is, independently for each occurrence, H or (C1-3o)acyl; provided that when R2 is (C]-30)acyl, R3 is H;
R4 and R5 each is, independently for each occurrence, H or (C1-4o)acyl; n is 4; and
X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, CH2NH2, or NH2; or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 2, wherein HN-CH((CH2)n-N(R4R5))-C(O) is
Lys(Nε-C(O)-(CH2)i2-CH3); or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 3, wherein said compound is:
[Aib10, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:3) [Aib17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:4)
[Aib11'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:5)
[4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:6)
[Aib22, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:7)
[A6c31, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:8) [A6c30, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:9)
[A6c28, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 10)
[Aib3, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:11)
[A6c24, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 12) [Aib6, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 13)
[Aib18, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 14)
[Aib29, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 15)
[Aib32, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 16)
[Aib23, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 17) [A6c17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 18)
[Aib11, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:19)
[Aib12, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:20)
[Aib14, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:21)
[Aib15, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:22) [Aib16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:23)
[Aib7, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:24)
[Aib9, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:25)
[Aib10'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:26)
[Aib15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:27) [Aibu'15, Nle17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:28)
[Aib10'15, NIe17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:29)
[Aib11'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:30)
[Aib12'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:31)
[Aib10'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:32) [Aib11>16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:33)
[Aib10'16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:34)
[Aib17, 4Hyp34, Apc35]hNPY(l-36)-NH2; (SEQ ID NO:36)
[Aib17, 4Hyp34, Aic36]liNPY(l-36)-NH2; (SEQ ID NO:37) [Aib17, 4Hyp34, 4>JH2Phe35]hNPY(l-36)-NH2; (SEQ ID NO:38) [Aib17, 4Hyp34, 4NH2CH2Phe35]hNPY(l-36)-NH2; (SEQ ID NO:39)
[Nip34]hNPY(l-36)-NH2; (SEQ ID NO:42)
[Inp34]hNPY(l-36)-NH2; (SEQ ED NO:43)
[Dhp34]hNPY(l -3O)-NH2; (SEQ ID NO:44)
[hPro34]hNPY(l-36)-NH2; (SEQ ID NO:45) [Tic34]hNPY(l-36)-NH2; or (SEQ ID NO:46) [Leu31, Lys34(Nε-C(O)-(CH2),2-CH3)]hNPY(l-36)-NH2; (SEQ ID NO:47) or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 2 or claim 3, wherein A34 is 4Hyp; or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 5, wherein said compound is:
[Aib10, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:3) [Aib17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:4)
[Aib11'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:5)
[4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:6)
[Aib22, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:7)
[A6c31, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:8) [A6c30, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:9)
[A6c28, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:10)
[Aib3, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:11)
[A6c24, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 12)
[Aib6, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 13) [Aib18, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:14)
[Aib29, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 15)
[Aib32, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 16)
[Aib23, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 17)
[A6c17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO: 18) [Aibn, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:19)
[Aib12, 4Hyp34]hNPY(l-36)-NH2; (SEQ ED NO:20)
[Aib14, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:21)
[Aib15, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:22)
[Aib16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:23) [Aib7, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:24)
[Aib9, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:25)
[Aib10>17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:26)
[Aib15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:27)
[Aib1 ll15, NIe17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:28) [Aib10'15, NIe17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:29)
[Aib11'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:30)
[Aib12'15'17, 4Hyp34]hNPY(l -3O)-NH2; (SEQ ID NO:31)
[Aib10'15'17, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:32) [Aib11>16, 4Hyp34]liNPY(l-36)-NH2; (SEQ ID NO:33)
[Aib10'16, 4Hyp34]hNPY(l-36)-NH2; (SEQ ID NO:34)
[Aib17, 4Hyp34, Apc35]hNPY(l-36)-NH2; (SEQ ID NO:36)
[Aib17, 4Hyp34, Aic36]hNPY(l-36)-NH2; (SEQ ID NO:37)
[Aib17, 4Hyp34, 4NH2Phe35]hNPY(l -3O)-NH2; or (SEQ ID NO:38) [Aib17, 4Hyp34, 4NH2CH2Phe35]hNPY(l-36)-NH2; (SEQ ID NO:39) or a pharmaceutically acceptable salt thereof.
7. A compound according to claim 1 or claim 2, wherein the peptide bond between A35 and A36 is replaced by a pseudopeptide bond; or a pharmaceutically acceptable salt thereof.
8. A compound according to claim 7, wherein A35- A36 is Lys-ψ(CH2-NH)Tyr or Lys-ψ(CH2-N(Ac))Tyr; or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 8, wherein said compound is:
[Aib11'17, 4Hyp34, Lys35-ψ(CH2-N(Ac))Tyr36]hNPY(l-36)-NH2; (SEQ ID NO:35)
[Aib17, 4Hyp34, Lys35-ψ(CH2-NH)Tyr36]hNPY(l-36)-NH2; or (SEQ ID NO:40)
[Aib11'17, 4Hyp34, Lys35-ψ(CH2-NH)Tyr36]hNPY(l-36)-NH2; (SEQ ID NO:41) or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1-9 or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition of claim 10, further comprising a pharmaceutically acceptable carrier.
12. A method of eliciting an agonist effect from a neuropeptide Y receptor in a subject in need thereof, which comprises administering to said subject a therapeutically effective amount of a compound according to any one of claims 1-9 or a pharmaceutical composition of claim 10 or claim 11.
13. A method of eliciting an antagonist effect from a neuropeptide Y receptor in a subject in need thereof, which comprises administering to said subject a therapeutically effective amount of a compound according to any one of claims 1-9 or a pharmaceutical composition of claim 10 or claim 11.
14. The method according to claim 12 or claim 13, wherein said neuropeptide Y receptor is the NPY-Yl receptor.
15. A method for treating a disorder or a disease mediated by neuropeptide Y- receptor binding, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-9 or a pharmaceutical composition of claim 10 or claim 11.
16. The method according to claim 15, wherein said neuropeptide Y receptor is the NPY-Yl receptor.
17. The method according to claim 15 or claim 16, wherein said disorder or disease pertains to the heart, blood vessels or the renal system, such as vasospasm, heart failure, shock, cardiac hypertrophy, increased blood pressure, angina, myocardial infarction, sudden cardiac death, arrythmia, peripheral vascular disease, impaired flow of fluid, abnormal mass transport, and renal failure.
18. The method according to claim 15 or claim 16, wherein said disorder or disease is related to increased sympathetic nerve activity.
19. The method according to claim 15 or claim 16, wherein said disorder or disease is related to the central nervous system, such as cerebral infarction, neurodegeneration, epilepsy, stroke, cerebral vasospasm, cerebral hemmorrhage, depression, anxiety, schizophrenia, and dementia.
20. The method according to claim 15 or claim 16, wherein said disorder or disease is related to pain or nociception.
21. The method according to claim 15 or claim 16, wherein said disorder or disease is related to abnormal gastrointenstinal motility and secretion, such as different forms of ileus, urinary incontinence, and Crohn's disease.
22. The method according to claim 15 or claim 16, wherein said disorder or disease pertains to abnormal drink and food intake disorders, such as anorexia and metabolic disorders.
23. The method according to claim 15 or claim 16, wherein said disorder or disease is related to sexual dysfunction and reproductive disorders.
24. The method according to claim 15 or claim 16, wherein said disorder or disease is associated with inflammation.
25. The method according to claim 15 or claim 16, wherein said disorder or disease is a respiratory disease, such as asthma and bronchoconstriction.
26. The method according to claim 15 or claim 16, wherein said disorder or disease is related to abnormal hormone release, such as leutinizing hormone, growth hormone, insulin, and prolactin.
27. The method according to claim 16, wherein said condition or disease is tumor expressing the NPY-Yl receptor.
28. The method of claim 27, wherein said tumor is breast cancer, ovarian cancer, or glioblastoma.
29. The method according to claim 16, wherein said condition or disease mediated by the NPY-Yl receptor binding is hypertension.
30. The method according to claim 15 or claim 16, wherein said condition or disease is obesity, hyperphasia, or bulimia.
PCT/US2010/000491 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution WO2010096186A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA201171075A EA019498B1 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution
US13/202,030 US8440611B2 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide Y having at least one synthetic amino acid substitution
AU2010216383A AU2010216383B2 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide Y having at least one synthetic amino acid substitution
JP2011551067A JP5480301B2 (en) 2009-02-20 2010-02-19 Analogs of neuropeptide Y having at least one synthetic amino acid substitution
CN201080008613.XA CN102325540B (en) 2009-02-20 2010-02-19 The analog of the neuropeptide tyrosine that the aminoacid with at least one synthesis is replaced
EP10744070A EP2398485A4 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution
CA2751636A CA2751636C (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution
UAA201111164A UA101435C2 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution
MX2011008776A MX2011008776A (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution.
KR1020117020922A KR101345253B1 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20815109P 2009-02-20 2009-02-20
US61/208,151 2009-02-20

Publications (1)

Publication Number Publication Date
WO2010096186A1 true WO2010096186A1 (en) 2010-08-26

Family

ID=42634167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000491 WO2010096186A1 (en) 2009-02-20 2010-02-19 Analogues of neuropeptide y having at least one synthetic amino acid substitution

Country Status (11)

Country Link
US (1) US8440611B2 (en)
EP (1) EP2398485A4 (en)
JP (1) JP5480301B2 (en)
KR (1) KR101345253B1 (en)
CN (1) CN102325540B (en)
AU (1) AU2010216383B2 (en)
CA (1) CA2751636C (en)
EA (1) EA019498B1 (en)
MX (1) MX2011008776A (en)
UA (1) UA101435C2 (en)
WO (1) WO2010096186A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5584236B2 (en) * 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Cytotoxic conjugates having neuropeptide Y receptor binding compounds
WO2020109546A1 (en) 2018-11-29 2020-06-04 University Of Copenhagen Treatment of cardiovascular diseases
CN111494606B (en) * 2020-04-24 2021-12-14 广州医科大学 New application of neuropeptide Y

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5328899A (en) 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
WO2002043776A2 (en) 2000-11-24 2002-06-06 Reubi Jean Claude Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer
US6511984B2 (en) 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US20060105942A1 (en) * 2002-07-23 2006-05-18 Claire Lewis Inhibition of cell division based use of analogs of neuropeptide y
US20060211610A1 (en) * 2003-01-17 2006-09-21 Dong Zheng X Peptide yy analogs
WO2007039318A2 (en) 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501281A (en) * 1993-06-18 1999-02-02 ユニバーシティ オブ シンシナティ Neuropeptide Y antagonists and agonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5328899A (en) 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US6511984B2 (en) 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists
WO2002043776A2 (en) 2000-11-24 2002-06-06 Reubi Jean Claude Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer
US20060105942A1 (en) * 2002-07-23 2006-05-18 Claire Lewis Inhibition of cell division based use of analogs of neuropeptide y
US20060211610A1 (en) * 2003-01-17 2006-09-21 Dong Zheng X Peptide yy analogs
WO2007039318A2 (en) 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2398485A4

Also Published As

Publication number Publication date
CA2751636C (en) 2016-08-30
JP5480301B2 (en) 2014-04-23
US20120040885A1 (en) 2012-02-16
US8440611B2 (en) 2013-05-14
EP2398485A4 (en) 2013-01-09
EA201171075A1 (en) 2012-04-30
CN102325540B (en) 2015-09-23
EA019498B1 (en) 2014-04-30
CN102325540A (en) 2012-01-18
JP2012518637A (en) 2012-08-16
AU2010216383B2 (en) 2013-06-20
MX2011008776A (en) 2011-10-24
UA101435C2 (en) 2013-03-25
EP2398485A1 (en) 2011-12-28
KR101345253B1 (en) 2013-12-31
KR20110125236A (en) 2011-11-18
AU2010216383A1 (en) 2011-09-15
CA2751636A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
JP5864506B2 (en) A truncated analog of a glucose-dependent insulinotropic polypeptide
JP5865324B2 (en) Glucose-dependent insulinotropic polypeptide analogs
JP5986550B2 (en) Glucose-dependent insulinotropic polypeptide (GIP) analog modified at the N-terminus
JP5881659B2 (en) Glucose-dependent insulinotropic polypeptide analog
EP2398492A1 (en) Cytotoxic conjugates having neuropeptide y receptor binding compound
US8440611B2 (en) Analogues of neuropeptide Y having at least one synthetic amino acid substitution
JP5422003B2 (en) Analogue of neuropeptide Y with proline substitution at position 34

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080008613.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10744070

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2751636

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011551067

Country of ref document: JP

Ref document number: MX/A/2011/008776

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010216383

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2010744070

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010744070

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117020922

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010216383

Country of ref document: AU

Date of ref document: 20100219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 7080/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201171075

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13202030

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1008880

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI1008880

Country of ref document: BR

Free format text: EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES (DANIEL B. DEOLIVEIRA ) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2010/096186 E O CONSTANTE DA PETICAO INICIAL NO 020110087369

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI1008880

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2513.